← Browse by Condition
Medical Condition

major depressive disorder

Total Trials
25
Recruiting Now
25
Trial Phases
Phase 1, Phase 2, Phase 4

ClinicalMetric tracks all active clinical trials for major depressive disorder sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — major depressive disorder Clinical Trials

How many clinical trials are currently recruiting for major depressive disorder?
ClinicalMetric currently tracks 25 actively recruiting clinical trials for major depressive disorder, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 25. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for major depressive disorder?
major depressive disorder research spans Phase 1 (2 trials), Phase 2 (5 trials), Phase 3 (3 trials), Phase 4 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a major depressive disorder clinical trial?
Eligibility criteria for major depressive disorder trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
5
Phase 3
3
Phase 4
3
Top Sponsors
National Institute of Mental Health (NIMH) 2 trials
Nova Scotia Health Authority 2 trials
Centre for Addiction and Mental Health 2 trials
University of Wisconsin, Madison 1 trial
University Hospital Tuebingen 1 trial

Recruiting Clinical Trials

NCT03973268 Phase 1
Recruiting
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Enrollment
70 pts
Location
United States
Sponsor
National Institute of Mental H...
View Trial →
NCT06110897
Recruiting
RESISTance Exercise for Depression Trial
Enrollment
200 pts
Location
United States
Sponsor
University of Wisconsin, Madis...
View Trial →
NCT06410599 Phase 2
Recruiting
Pharmacologic Treatment Augmentation in Chronic Depression
Enrollment
60 pts
Location
Germany
Sponsor
University Hospital Tuebingen
View Trial →
NCT00018057 Phase 2
Recruiting
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Enrollment
3,500 pts
Location
United States
Sponsor
National Institute of Mental H...
View Trial →
NCT04576182
Recruiting
Supportive-Expressive and Emotion-Focused Treatment for Depression
Enrollment
124 pts
Location
Israel
Sponsor
University of Haifa
View Trial →
NCT07305701
Recruiting
Cohort Study on Medical Students' Mental Health
Enrollment
10,000 pts
Location
France
Sponsor
Centre Hospitalier Régional d'...
View Trial →
NCT06480500 Phase 2
Recruiting
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Enrollment
110 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT05892744 Phase 4
Recruiting
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Enrollment
50 pts
Location
United States
Sponsor
University of Texas at Austin
View Trial →
NCT07633080
Recruiting
Magnesium Bisglycinate in Major Depressive Disorder
Enrollment
84 pts
Location
India
Sponsor
All India Institute of Medical...
View Trial →
NCT04061148
Recruiting
Near Infrared Spectroscopy (NIRS) for Assessment of Depression
Enrollment
90 pts
Location
United States
Sponsor
University of California, San ...
View Trial →
NCT06559826 Phase 2
Recruiting
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
Enrollment
70 pts
Location
United States
Sponsor
Icahn School of Medicine at Mo...
View Trial →
NCT03601026
Recruiting
Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
Enrollment
120 pts
Location
Canada
Sponsor
Nova Scotia Health Authority
View Trial →
NCT06775379 Phase 3
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Enrollment
450 pts
Location
United States
Sponsor
Xenon Pharmaceuticals Inc.
View Trial →
NCT04972136
Recruiting
rTMS for Depression in Young Adults With Autism
Enrollment
80 pts
Location
Canada
Sponsor
Centre for Addiction and Menta...
View Trial →
NCT06086366
Recruiting
Presynaptic Imaging in Major Depressive Episodes After COVID-19
Enrollment
90 pts
Location
Canada
Sponsor
Centre for Addiction and Menta...
View Trial →
NCT06963021 Phase 3
Recruiting
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Enrollment
200 pts
Location
United States, Belgi...
Sponsor
Neurocrine Biosciences
View Trial →
NCT05004987 Phase 4
Recruiting
Aβ Dynamics in LLMD
Enrollment
60 pts
Location
United States
Sponsor
NYU Langone Health
View Trial →
NCT04041479 Phase 3
Recruiting
Biomarker-guided rTMS for Treatment Resistant Depression
Enrollment
348 pts
Location
United States
Sponsor
Weill Medical College of Corne...
View Trial →
NCT04637620 Phase 2
Recruiting
NMDA Modulation in Major Depressive Disorder
Enrollment
90 pts
Location
Taiwan
Sponsor
China Medical University Hospi...
View Trial →
NCT05527509
Recruiting
Risk and Resiliency Factors in the RCMP: A Prospective Investigation
Enrollment
960 pts
Location
Canada
Sponsor
University of Regina
View Trial →
NCT05017311 Phase 4
Recruiting
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Enrollment
400 pts
Location
Canada
Sponsor
Nova Scotia Health Authority
View Trial →
NCT05523817
Recruiting
Targeting Specific Brain Networks to Treat Specific Symptoms in Depression
Enrollment
80 pts
Location
United States
Sponsor
Massachusetts General Hospital
View Trial →
NCT06050070
Recruiting
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
Enrollment
58 pts
Location
United States
Sponsor
University of Michigan
View Trial →
NCT07444242
Recruiting
Accelerated Treatment of Depressive Patients With tDCS
Enrollment
30 pts
Location
Germany
Sponsor
University of Regensburg
View Trial →
NCT06480201 Phase 1
Recruiting
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Enrollment
100 pts
Location
United States
Sponsor
Texas A&M University
View Trial →

Related Conditions

treatment resistant depression (3) generalized anxiety disorder (2) depression (1) major depression (1) anxiety disorders (1) suicidal ideation (1) alcoholism (1) marijuana abuse (1) loneliness (1) suicide (1) chronic major depression recurrent (1) mental illness (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology